 |
      
|
|
|
|
|
|||||
|
|
September 25, 2002
Neurochem files Investigational New Drug application for Cerebril™ to treat
Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy. About Cerebril™
Cerebril™ is a small organic molecule that has been designed to modify the course of
Hemorrhagic Stroke due to CAA by interfering with the association between glycosaminoglycans
(GAGs) and Aß amyloid protein in the blood vessels of the brain of patients with CAA.
As part of a "disease modifying" class of drug candidates, Cerebril™ is expected
to act at two levels: to prevent and stop the formation and deposition of amyloid fibrils
and in binding to soluble Aß, to inhibit the inflammatory response associated with
amyloid build-up in Hemorrhagic Stroke due to CAA. Cerebril™ is an oral, safe drug
candidate that has simple manufacturing and a good pharmacokinetic profile. Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy
Hemorrhagic Stroke due to CAA, is characterized by the progressive invasion of the blood
vessel walls in the brain by amyloid fibrils. The blood vessels becomes brittle and lead to
recurrent strokes and potentially devastating lobar hemorrhages in the brain. It is considered
a major type of stroke for which there is no effective treatment. While up to 80 percent of
lobar hemorrhages are not fatal the first time, they are frequently recurrent and carry very
high morbidity and mortality rates. About Neurochem
Neurochem is an industry leader in the development of therapeutic drugs and diagnostic tools
for central nervous system (CNS) and amyloid-related diseases associated with aging. The
Company has to date advanced three drug candidates to clinical trials: Fibrillex™, for
the life-threatening orphan disease, secondary amyloidosis in a pivotal Phase II/III clinical
trial, Alzhemed™, for the treatment of Alzheimer's Disease advancing to Phase II clinical
trials, and Cerebril™, for hemorrhagic stroke also advancing to Phase II clinical
trials. The Company has built a strong product pipeline by developing a novel, proprietary
series of compounds that inhibit the formation, deposition and toxic effects of amyloid
fibrils within the body. Neurochem's overall therapeutic programs target CNS disorders
including Alzheimer's disease, epileptic seizures caused by head trauma or acute brain
injury, and hemorrhagic stroke (due to cerebral amyloid angiopathy), and other
life-threatening diseases including systemic amyloidosis and amyloid-associated diabetes
type II. (www.neurochem.com).
All of the statements contained in this news release, other than statements of fact which
are independently verifiable at the date hereof, are forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown. Some examples of known risks are: the
impact of general economic conditions, general conditions in the pharmaceutical industry, changes
in the regulatory environment in the jurisdictions in which Neurochem does business, stock
market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation or otherwise. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
